The use of desmopressin as a hemostatic agent: A concise review

American Journal of Hematology

Volumn 82, Issue 8, 2007, Pages 731-735

  Franchini, Massimo ^a,b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b OSPEDALE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; HEMOSTATIC AGENT; HEPARIN; TICLOPIDINE; VASOPRESSIN DERIVATIVE; VON WILLEBRAND FACTOR;

AFIBRINOGENEMIA; BERNARD SOULIER DISEASE; BLEEDING; BLEEDING DISORDER; BLEEDING TIME; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG INDICATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; LIVER CIRRHOSIS; MAY HEGGLIN ANOMALY; OCULAR ALBINISM; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; UREMIA; VON WILLEBRAND DISEASE;

DEAMINO ARGININE VASOPRESSIN; DRUG TOXICITY; HEMOPHILIA A; HEMORRHAGE; HEMOSTATICS; HUMANS; VON WILLEBRAND DISEASE;

EID: 34547673114     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20940     Document Type: Review

References (74)

1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997;90:2515-2521.
2. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174.
3. Cash JD, Garder AM, da Costa J. The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 1974;27:363-364.
4. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977;1:869-872.
5. Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991;5:155-161.
6. Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Sem Hematol 2005;42:29-35.
7. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003;1:682-689.
8. Sutor AH. DDAVP is not a panacea for children with bleeding disorders. Br J Haematol 2000;108:217-227.
9. Pasi JK, Collins PW, Keeling DM, et al. Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004;10:218-231.
10. Federici AB, Castaman G, Mannucci PM, Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002;8:607-621.
11. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001;97:1915-1919.
12. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-253.
13. Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001;66:280-284.
14. Federici AB. Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004;103:2032-2038.
15. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992;82:87-93.
16. Mannucci PM, Federici AB. Management of inherited von Willebrand disease. Best Pract Res Clin Haematol 2001;14:455-462.
17. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996;76:692-696.
18. Warrier I, Lusher JM. DDAVP-a useful alternative to blood components in moderate hemophilia A and von Willebrand's disease. J Pediatr 1983;102:228.
19. Mariani G, Ciavarella N, Mazzucconi MG, et al. Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in hemophilia and von Willebrand disease. A study of 43 patients. Clin Lab Haematol 1984;6:229-238.
20. de la Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand disease to treatment with desmopressin. Ann Intern Med 1985;103:6-14.
21. Villar A, Jimenez-Yuste V, Quintana M, Hernandez-Navarro F. The use of haemostatic drugs in haemophilia: Desmopressin and antifibrinolytic agents. Haemophilia 2002;8:189-193.
22. Lethagen S. Desmopressin in mild hemophilia A: Indications, limitations, efficacy, and safety. Semin Thromb Hemost 2003;29:101-106.
23. Schulman S. DDAVP - The multipotent drug in patients with coagulopathies. Transfus Med Rev 1991;2:132-144.
24. Mannucci PM, Vicente V, Alberca I, et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: Pharmacokinetics and factor VIM responses. Thromb Haemost 1987;58:1037-1039.
25. Revel-Vilk S, Blanchette VS, Sparling C, Stain AM, Carcao MD. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol 2002;117:947-951.
26. Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica 2002;87:1122-1124.
27. Cattaneo M, Pareti FI, Zighetti M, Lecchi A, Lombardi R, Mannucci PM. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: Correlation with the bleeding time. J Lab Clin Med 1995;125:540-547.
28. Rao AK, Ghosh S, Sun L, et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. Thromb Haemost 1995;74:1071-1078.
29. Lethagen S, Nilsson IM. DDAVP-induced enhancement of platelet retention: Its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 1992;49:7-13.
30. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998;91:4397-4418.
31. Stine KC, Becton DL. DDAVP therapy controls bleeding in Ehlers-Danlos syndrome. J Pediatr Hematol Oncol 1997;19:156-158.
32. Yasui H, Adachi Y, Minami T, Ishida T, Kato Y, Imai K. Combination therapy of DDAVP and conjugated estrogens for a recurrent large subcutaneous hematoma in Ehlers-Danlos syndrome. Am J Hematol 2003;72:71-72.
33. Franchini M, Lippi G, Veneri D. Efficacy of desmopressin in preventing hemorrhagic complications in a patient with Marfan syndrome undergoing cardiac surgery. Blood Coagul Fibrinolysis 2006;17:325-326.
34. Castaman G, Ruggeri M, Rodeghiero F. Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency. Br J Haematol 1996;94:168-170.
35. Franchini M, de Gironcoli M, Lippi G, Manzato F, Aprili G, Gandini G. Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency. Haematologica 2000;85:106-107.
36. Castaman G, Rodeghiero F. Failure of DDAVP to shorten the prolonged bleeding time of two patients with congenital afibrinogenemia. Thromb Res 1992;68:309-315.
37. Michiels JJ, Budde U, van der Planken M, van Vliet H, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: Clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001;14:401-436.
38. Federici AB, Budde U, Rand JH. Acquired von Willebrand syndrome 2004: International registry. Hämostaseologie 2004;24:50-55.
39. Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: A concise review. Am J Hematol 2005;80:55-63.
40. Mudad R, Kane WH. DDAVP in acquired haemophilia A: Case report and review of the literature. Am J Hematol 1993;43:295-299.
41. Gandini G, Franchini M, Manzato F, Lippi G, Aprili G. A successful combination of prednisone, high-dose intravenous immunoglobulin and desmopressin in the treatment of acquired haemophilia A with high-titer inhibitor. Haematologica 1999;84:1054.
42. Mannucci PM. Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988;72:1449-1455.
43. de Franchis F, Arcidiacono PG, Carpinelli L, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double-blind study. New Italian Endoscopic Club. Hepatology 1993;18:1102-1107.
44. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986;67:1148-1153.
45. Schulman S, Johnsson H. Heparin, DDAVP and the bleeding time. Thromb Haemost 1991;65:242-244.
46. Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F. Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. Haematologica 1997;82:584-587.
47. Koh MBC, Hunt BJ. The management of perioperative bleeding. Blood Rev 2003;17:179-185.
48. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth 2004;93:842-858.
49. Porte RJ, Leebeek FWG. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002;62:2193-2211.
50. Zimmerman MA, Albright TN, Raeburn CD, Selzman CH. Vasopressin in cardiovascular patients: Therapeutic implications. Expert Opin Pharmacother 2002;3:505-512.
51. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: A double-blind randomized trial. N Engl J Med 1986;314:1402-1406.
52. Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery - A metanalysis of double-blind, placebo-controlled trials. Thromb Haemost 1995;74:1064-1070.
53. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome. The International Study of Perioperative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-1267.
54. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A metaanalysis of clinically relevant endpoints. Lancet 1999;354:1940-1947.
55. Carless PA, Henry DA, Moxey AJ, et al. Desmopressin for minimising periopeartive allogeneic blood transfusion. Cochrane Database Syst Rev 2004;1:CD001884.
56. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991;84:2063-2070.
57. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994;90:921-927.
58. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-1588.
59. Kobrinsky NL, Letts RM, Patel LR, et al. 1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med 1987;107:446-450.
60. Guay J, Reinberg C, Rivard GE, Poitras B, Mathews S, David M. DDAVP does not reduce bleeding during spinal fusion for idiopathic scoliosis. Can J Anaesth 1990;37:S14.
61. Flordal PA, Ljungstrom KG, Ekman B, Neander G. Effects of desmopressin on blood loss in hip arthroplasty. Controlled study in 50 patients. Acta Orthop Scand 1992;63:381-385.
62. Karnezis TA, Stulberg SD, Wixson RL, Reilly P. The hemostatic effects of desmopressin on patients who had total joint arthroplasty. A double-blind randomized trial. J Bone Joint Surg Am 1994;76:1545-1550.
63. Schott U, Sollen C, Axelsson K, Rugarn P, Allvin I. Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran. Acta Anaesthesiol Scand 1995;39:592-598.
64. Zohar E, Fredman B, Ellis MH, Ifrach N, Stern A, Jedeikin R. A comparative study of the postoperative allogeneic blood-sparing effects of tranexamic acid and of desmopressin after total knee replacement. Transfusion 2001;41:1285-1289.
65. Lethagen S, Rugarn P, Bergqvist D. Blood loss and safety with desmopressin or placebo during aorto-iliac graft surgery. Eur J Vasc Surg 1991;5:173-178.
66. Clagett GP, Valentine RJ, Myers SI, Chervu A, Heller J. Does desmopressin improve hemostasis and reduce blood loss from aortic surgery? A randomized, double-blind study. J Vasc Surg 1995;22:223-229.
67. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989;31:199-202.
68. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: A case report and review of 40 patients. Haemophilia 2000;6:11-14.
69. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988;318:121.
70. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988;28:63-65.
71. Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989;2:675.
72. van Dantzig JM. Desmopressin and myocardial infarction. Lancet 1989;1:664-665.
73. Franchini M, Krampera M, Veneri D. Deep vein thrombosis after orthopedic surgery in a patient with type I Willebrand disease and mutation in the MTHFR and beta-fibrinogen genes. Thromb Haemost 2003;90:963.
74. Ray JC. DDAVP use during pregnancy: An analysis of its safety from mother and child. Obstet Gynecol Surg 1988;53:450-455.